Experts solve mystery of ancient 'mummified dragon' discovered by Japanese shogun
Researchers believe they've cracked the mystery of a mummified "rainbow dragon" that's been sitting in a Japanese treasure house for centuries.
The "dragon" has been stashed at the Shosoin Treasure House in the historic Japanese city of Nara, according to Pen News. The remains were reportedly found by Yoshinori Ashikaga, a 15th-century shogun, in 1429.
Legend states that Ashikaga cut a piece from the Ranjatai, a rare and valuable piece of agarwood, at the time of the skeleton's discovery. The shogun was visiting the Todai-ji temple in Nara at the time.
Shortly after, a monk at the temple claimed to have seen "something in the shape of a small dragon" that was dried by the sun. Ashikaga took the skeleton and preserved it.
But was the skeleton a dragon after all? Researchers say not quite.
A recently published study said the "dragon" was actually a female Japanese marten.
The fluffy, weasel-like animal is native to central and southern Japan.
"The two premolars are clearly visible, and this characteristic indicates that it is a species of the Martes genus," the study states.
Using x-ray technology and radiocarbon dating, researchers found that the marten dated back to the 11th or 12th centuries.
The Todai-ji temple underwent heavy renovations at the time, according to Pen News. Experts believe the animal entered the building and was trapped before it died and was mummified.
Pictures show the marten missing its forelegs, making it resemble a dragon.
Legend states that rain would descend upon the treasure house every time the skeleton's repository was opened – and during the study, researchers fought heavy downpours that made traveling from Tokyo to Nara difficult.
Mami Tsuru, a conservationist at the Shosoin Treasure House, told Pen News she's certain the skeleton is the same one recorded by the Todai-ji monk.
"The age determination has significantly increased the possibility that the mummy is the sun-dried dragon-looking object recorded in the document from the Muromachi Period," the expert said.
Tsuru added, "We believe this is a good example of how Shosoin has protected not only beautiful items, but also all the items inside the repository."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
INFIDIGIT, INDIA'S LEADING SEO COMPANY, CONTINUES TO INNOVATE WITH CLIENT-CENTRIC DEVELOPMENTS THROUGH INFIGROWTH
MUMBAI, India, June 2, 2025 /PRNewswire/ -- Infigrowth, the digital growth platform developed by Infidigit, India's leading SEO agency, has introduced its SEO Audit Module — a comprehensive, AI-powered solution designed to help brands precisely identify and resolve SEO issues impacting online visibility and performance. The SEO Audit Module offers a comprehensive site health checkup that helps brands gain clear insights into their website's performance. By analysing critical SEO factors through advanced AI-driven technology, it highlights key areas for improvement and provides actionable recommendations. This empowers businesses to enhance their search rankings and maintain a strong digital presence. The key features of our Automated SEO Audit Module include: 200+ Pointers Checked — Covers speed, mobile-friendliness, content, backlinks, and user experience. Weekly and Monthly Reports — Track SEO progress regularly. Clear Fix Recommendations — Step-by-step guidance for quick fixes. Issue Prioritisation — Focus on the most critical problems first. Page-Level Insights — Analyse and optimise individual pages. Team Collaboration — Share audits and work together in real-time. Kaushal Thakkar, CEO, Infidigit, said, "With over a decade of experience in SEO and digital marketing, Infidigit has a deep understanding of the challenges brands face in today's digital ecosystem. Infigrowth was created to address these challenges by offering a platform that combines AI-driven diagnostics with practical recommendations. Our SEO Audit Module enables brands to make data-driven decisions that lead to measurable growth, improved user experience, and a stronger online presence. It helps businesses stay agile and competitive in a constantly evolving landscape." Leveraging Infidigit's deep industry expertise and Infigrowth's AI capabilities, the SEO Audit Module delivers precise insights and actionable steps that enable brands to optimise their digital strategies, adapt swiftly to market shifts, and drive sustainable growth. Beyond the SEO Audit Module, Infigrowth provides a full suite of AI-powered features — including AI Overview tracking, SearchSense, RankTracker, and SERP Comparison. They are complemented by AI-driven keyword suggestions, seasonal trend tracking, competitor benchmarking, comprehensive SERP insights, and instant ranking alerts. Together, these features provide brands with a comprehensive and proactive SEO management experience. Looking ahead, Infidigit remains committed to continuous innovation and plans to introduce more advanced features on Infigrowth tailored to the evolving needs of digital marketers and businesses aiming to maintain a competitive edge. About Infigrowth Infigrowth is a cutting-edge digital growth platform developed by Infidigit, one of India's premier Digital Marketing agencies. Specialising in AI-powered SEO and data-driven marketing solutions, Infigrowth helps brands optimise their online presence, improve search rankings, and achieve measurable business growth. With a focus on innovation, actionable insights, and comprehensive digital tools, Infigrowth empowers businesses across industries to stay competitive in the evolving digital landscape. About Infidigit Founded in 2017, Infidigit is an AI-enabled digital growth partner that empowers top brands to achieve impactful results across SEO, Content, PPC, ASO, CRO, Website Development, and data-driven marketing strategies. As a pioneer in AI innovation within marketing, Infidigit has developed Infigrowth — a SaaS platform designed to simplify SEO for businesses of all sizes. Over the years, Infidigit has partnered with startups, MSMEs, and enterprises across diverse industries, helping them thrive in the fast-evolving digital economy. The company's commitment to excellence is demonstrated through over 65+ award-winning campaigns, recognised by prestigious platforms including SMX, APAC Search Awards, ET BrandEquity Shark Awards, Sparkies, and E4M IDMA. Video: View original content to download multimedia:
Bloomberg
3 hours ago
- Bloomberg
China's Coal Industry Has a Big, Dirty Secret
Exactly a century ago, two German chemists patented a process to transform coal into liquid fuels. Following its discovery in 1925, the Fischer-Tropsch synthesis eventually became infamous: The Nazis used it to fuel their war machine, and apartheid South Africa turned to it to offset the impact of an oil embargo in the 1980s. Its last — and huge — user is China. Largely unnoticed, the size of this obscure corner of the Chinese coal industry has reached gargantuan proportions: It consumes about 380 million metric tons of coal as a feedstock for chemical and liquid fuel production, according to the International Energy Agency. To understand its size better, it helps to think about the segment as if it were a country. As such, it would rank as the world's third-largest consumer, only behind the rest of the Chinese coal sector and India, but ahead of the US, Japan and other top coal-consuming nations like Indonesia and Turkey. It's not a little dirty secret — it's a big one, with significant implications for global climate and energy policy. The longer China remains addicted to coal, the more difficult it will be to decrease carbon dioxide emissions. Despite its huge progress in green energy, from electric cars to solar panels, the Asian giant consumes more coal than every other country on the planet combined. Crucially, the Chinese coal-conversion industry is set to expand even further, potentially offsetting declines elsewhere in the country, including a reduction in coal demand to produce cement and steel. 'We expect a growth between 5% and 10% in the coming years,' Carlos Fernandez Alvarez, head of coal at the IEA, tells me. Unfortunately, the sector is a black hole, as China publishes scant statistical information about it. For decades, China has converted some of its coal into chemical products and liquid fuels in what scholars call the 'traditional' coal chemical industry. The starting point was almost always metallurgical coal, converted into coke, and further transformed into ammonia-based fertilizers and acetylene-based chemicals. Yet over the last two decades, China has built a second layer, typically referred to as the 'modern' coal chemical industry, based on new variations of the old Fischer-Tropsch process plus sophisticated new methods, including methanol synthesis to produce petrochemical goods, such as olefins, used in turn to make plastics. The modern part of that processing was largely experimental in the early 2000s. Commercial-scale projects mushroomed in the 2010s, and, after a brief hiatus, more have emerged in recent years, particularly in the Chinese heartland, where the bulk of the country's coal fields are located far from coastal cities. By now, its scale — which dwarfs all other countries' coal-to-chemicals production — and growth is surprising even veteran industry observers. Look at some modernized plants and coal is nowhere to be seen: It's mined underground almost directly beneath the chemical facilities, carried by conveyor into the furnaces where it's gasified and transformed. From there, it goes into your plastic water bottle or synthetic fabric clothes. 1
Associated Press
4 hours ago
- Associated Press
Latest Data of InnoCare's Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
BEIJING--(BUSINESS WIRE)--Jun 1, 2025-- Latest data of InnoCare's robust oncology pipelines were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, involving the anti-CCR8 antibody ICP-B05 (CM369), the BCL2 inhibitor mesutoclax (ICP-248) and the pan-TRK inhibitor zurletrectinib (ICP-723). Oral Presentation Title: Preliminary results from the dose-escalation stage of a phase I trial of an anti-CCR8 antibody in patients with relapsed/refractory cutaneous T-cell lymphoma (R/R CTCL) (Abstract No.: 2514) The current study is the first and only report on the preliminary efficacy data of anti-CCR8 targeted therapy for CTCL patients. The efficacy of ICP-B05 was supported by the PD effects in both skin lesions and peripheral blood in the depletion of CCR8+ cells. ICP-B05 is safe and well tolerated and its safety profile made it a good candidate for combo therapies for CTCL patients with lymph node and other organ involvement. As of Jan. 6, 2025, a total of 13 patients with R/R CTCL were treated. There were 12 patients received at least one skin lesion assessment followed the mSWAT. 33.3% of patients achieved PR, and 58.3% of patients were assessed as SD with reduction in skin lesion. The 6-month PFS rate was 82.5%, and the median PFS was 11.4 months. Among the five patients with CCR8+ levels exceeding 10%, four (80%) achieved PR. PK analysis showed that serum exposure (Cmax and AUC0-14D) increased with dose escalation. PD analysis demonstrated significant depletion of CCR8-expressing cells in CTCL skin lesions. Poster 1: Title: Preliminary safety and efficacy data of ICP-248, a novel BCL2 inhibitor, in patients with relapsed or refractory B-cell malignancies (Abstract No.: 7038) The results of ICP-248 monotherapy suggests a well-tolerated safety profile and an exciting efficacy in BTK failed, heavily treated, relapsed or refractory B-cell malignancies. As of April 15, 2025, a total of 68 patients were enrolled in the dose escalation and dose expansion study. 17 R/R CLL/SLL and 32 R/R MCL patients were treated with 125 mg of ICP-248, including 10 CLL/SLL and 25 MCL patients were previously treated with BTK inhibitors, and 70.0% of CLL/SLL patients and 100% of MCL patients were resistant to BTK inhibitors. 17 CLL/SLL and 26 MCL patients had at least one response assessment. Among the BTK naïve patients, the ORR for R/R CLL/SLL and R/R MCL patients were both 100%, and the CRR was 14.3% and 71.4% respectively, of which 43% of MCL patients reported undetectable minimal residual disease (uMRD). Among the BTK treated patients, the ORR for R/R CLL/SLL and R/R MCL patients were 100% and 78.9% respectively, and the CRR were 30.0% and 26.3% respectively, of which uMRD was reported in 20% of CLL/SLL and 16% of MCL patients. The median PFS of R/R MCL patients who had received treatment of BTK inhibitors before was 8.3 months. The PFS was not reached among BTK naïve R/R CLL/SLL and R/R MCL patients and BTK-treated R/R CLL/SLL patients. Poster 2: Title: Efficacy, safety and pharmacokinetics (PK) of zurletrectinib, a next-generation pan-TRK inhibitor, in pediatric and adolescent patients with NTRK fusion-positive (NTRK+) solid tumors (Abstract No.: 10048) The integrated analysis demonstrated that zurletrectinib had significant efficacy and good safety profile in pediatric and adolescent patients with NTRK+ solid tumors. Zurletrectinib also showed the potential to overcome the resistance to first generation TRK inhibitors. These findings support zurletrectinib is a better treatment option for NTRK+ pediatric and adolescent patients. As of Nov. 23, 2024, 18 patients in total were enrolled, including 8 pediatric patients and 10 adolescent patients. Among the 18 patients, 6 TRK inhibitor treatment-naïve patients with central lab confirmed NTRK+ were efficacy evaluable. The confirmed ORR assessed by IRC was 100%. All patients achieved partial response (PR) at the first tumor assessment and maintained the remission as of the cutoff date. Median time to response were 1.0 month in adolescent patients and 0.9 month in pediatric patients. It is worth noting that one pediatric patient who progressed on prior first-generation TRK inhibitor achieved complete response after receiving zurletrectinib. Poster 3: Title: Updated efficacy and safety of zurlectrectinib in adult patients (pts) with locally advanced or metastatic NTRK fusion-positive (NTRK+) solid tumors (Abstract No.: 3112) In line with previously reported results, zurletrectinib continued to demonstrate a deep and durable responses in adult patients with NTRK+ advanced solid tumors with or without brain metastasis. Zurletrectinib was also well-tolerated and showed favorable safety profile in adult patients with various tumor types. As of Nov. 23, 2024, a total of 49 TRK inhibitor naïve adult patients were evaluable for efficacy representing 12 different solid tumor types. Among the efficacy population, the distribution of NTRK1, NTRK2 and NTRK3 fusions was 53.1%, 2.0% and 44.9% respectively. The confirmed ORR by IRC was 83.7%, with CR of 10.2%. Median duration of response (DOR) and median progression-free survival (PFS) by IRC were not reached. The DOR rate and PFS rate by IRC at 12 months was 92.0% and 90.5% respectively. Two of the three patients who had brain metastasis at the baseline achieved intracerebral ORR, which is consistent with the good brain penetration and strong intracranial activity of zurletrectinib. The 2025 ASCO Annual Meeting is held from May 30 to June 3, 2025 in Chicago, U.S. The ASCO annual meeting is the most important and professional academic event in the global oncology field, which showcases the international cutting-edge clinical oncology research results and tumor treatment technologies. About InnoCare InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States. InnoCare Forward-looking Statements This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. View source version on CONTACT: Media Chunhua Lu 86-10-66609879 [email protected] 86-10-66609999 [email protected] KEYWORD: CHINA ASIA PACIFIC INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY GENERAL HEALTH HEALTH CLINICAL TRIALS SOURCE: InnoCare Pharma Copyright Business Wire 2025. PUB: 06/01/2025 08:30 PM/DISC: 06/01/2025 08:31 PM
